SearchDictionaryMobileLogin

Salvatore Cuzzocrea Selected Research

Shock

01/2007The role of 5-lipoxygenase and leukotrienes in shock and ischemia-reperfusion injury.
01/2007Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice.
10/2006A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock.
04/2006Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice.
01/2006Peroxisome proliferator-activated receptors and shock state.
12/2005Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock.
07/2005Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion.
05/2005The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock.
11/2004Glucocorticoid-induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock.
10/2004WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock.
02/2004Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.
01/2004Protective effects of M40401, a selective superoxide dismutase mimetic, on zymosan-induced nonseptic shock.
09/20035-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock.
09/2003Tyrphostin reduces the organ injury in haemorrhagic shock: role of inducible nitric oxide synthase.

Articles by Research Topic

Disease

22Reperfusion Injury
10/2008 - 03/2002
21Spinal Cord Injuries (Spinal Cord Injury)
09/2008 - 10/2004
16Pancreatitis
01/2008 - 05/2002
15Colitis
09/2008 - 07/2002
15Inflammation
02/2008 - 01/2002
14Ischemia
10/2008 - 11/2002
14Shock
01/2007 - 09/2003
8Multiple Organ Failure (MODS)
05/2008 - 10/2002
7Pneumonia (Pneumonitis)
02/2008 - 08/2003
6Septic Shock (Toxic Shock Syndrome)
10/2006 - 04/2003
5Periodontitis
02/2007 - 06/2005
5Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
01/2007 - 07/2002
5Pleurisy (Pleuritis)
10/2006 - 01/2003
4Arthritis (Polyarthritis)
07/2006 - 12/2003
4Experimental Arthritis
08/2005 - 10/2002
3Syndrome
11/2006 - 06/2004
2Pain (Aches)
09/2008 - 06/2004
2Endotoxemia
02/2008 - 11/2004
2Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2007 - 12/2004
2Rheumatoid Arthritis
08/2005 - 01/2005
2Tissue Adhesions
06/2005 - 12/2003
1Hypersensitivity (Allergy)
09/2008
1Melanoma (Melanoma, Malignant)
06/2008
1Glioma (Gliomas)
01/2008
1Edema
09/2007
1Carcinoma (Carcinomatosis)
08/2006
1Hemorrhage
05/2006

Drug/Important Bio-Agent (IBA)

15ZymosanIBA
05/2008 - 10/2002
13Caerulein (Ceruletide)IBA
01/2008 - 05/2002
10Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA
01/2007 - 06/2003
9CarrageenanIBA
02/2008 - 01/2003
8MelatoninIBA
09/2008 - 02/2002
8Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2007 - 01/2003
8PPAR alphaIBA
09/2007 - 07/2002
7PPAR gammaIBA
05/2004 - 07/2002
6Peroxisome Proliferator-Activated Receptors (PPAR)IBA
05/2007 - 07/2002
6LigandsIBA
05/2007 - 07/2002
6Superoxide DismutaseIBA
06/2005 - 07/2002
5Glycogen Synthase (Synthase I)IBA
12/2007 - 05/2006
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2007 - 01/2007
5Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
02/2007 - 12/2004
5poly ADP-ribose glycohydrolaseIBA
01/2007 - 06/2004
5pyrrolidine dithiocarbamic acidIBA
06/2006 - 01/2002
5rosiglitazone (Avandia)FDA Link
05/2004 - 09/2003
5Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
02/2004 - 03/2002
4Peroxynitrous Acid (Peroxynitrite)IBA
09/2008 - 10/2006
4Thalidomide (Thalomid)FDA Link
09/2008 - 06/2005
4Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
06/2008 - 11/2004
4TNFR-Fc fusion protein (etanercept)FDA Link
05/2008 - 03/2006
4TeaIBA
10/2006 - 01/2005
4M 40403IBA
06/2005 - 07/2002
4GW 274150IBA
01/2005 - 10/2002
4Superoxides (Superoxide)IBA
08/2004 - 01/2003
3Interleukin-10 (Interleukin 10)IBA
02/2008 - 07/2002
3Interleukin-6 (Interleukin 6)IBA
12/2007 - 06/2002
3Dexamethasone (Maxidex)FDA LinkGeneric
09/2007 - 06/2005
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2007 - 11/2003
3AG 127 (AG 126)IBA
06/2007 - 11/2003
3OxygenIBA
11/2006 - 06/2004
3Collagen Type II (Type II Collagen)IBA
07/2006 - 12/2003
38-chlorocarbochromen (AD 6)IBA
04/2006 - 03/2003
3ErythropoietinIBA
04/2006 - 12/2004
3cyclopentenoneIBA
05/2005 - 05/2002
35-aminoisoquinolinoneIBA
12/2004 - 11/2002
3MethylguanidineIBA
11/2004 - 01/2004
2palmidrolIBA
07/2008 - 09/2007
2Poly Adenosine Diphosphate RiboseIBA
06/2008 - 10/2004
2AG 556IBA
06/2007 - 11/2005
2TyrphostinsIBA
06/2007 - 11/2005
2LeukotrienesIBA
01/2007 - 01/2006
2Peroxisome ProliferatorsIBA
11/2006 - 07/2005
2tempolIBA
10/2005 - 08/2004
2CalpainIBA
04/2005 - 08/2004
2Streptozocin (Streptozotocin)FDA Link
03/2005 - 02/2004
2NADPH Oxidase (NAD(P)H oxidase)IBA
02/2005 - 10/2003
2zileuton (Zyflo)FDA Link
11/2004 - 08/2004
2M40401IBA
09/2004 - 01/2004
2calpain inhibitorsIBA
01/2004 - 10/2002
2Lipoproteins (Lipoprotein)IBA
12/2003 - 07/2003
1dihydroceramide desaturaseIBA
10/2008
1fumonisin B1IBA
10/2008
1Matrix MetalloproteinasesIBA
09/2008
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
09/2008
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
09/2008
1cyclopentanoneIBA
08/2008
1Protein Kinases (Protein Kinase)IBA
04/2008
1sphingosine phosphorylcholineIBA
02/2008
1infliximab (Remicade)FDA Link
01/2008
1AutoantibodiesIBA
12/2007
1Glutathione (Reduced Glutathione)IBA
08/2007
1alanylaspartic acidIBA
03/2007
1Xanthine DehydrogenaseIBA
02/2007
1Glycogen Synthase KinasesIBA
01/2007
13-aminobenzamideIBA
11/2006
1irinotecan (Camptosar)FDA LinkGeneric
08/2006
1temozolomide (Temodar)FDA Link
08/2006
1RelaxinIBA
08/2006
1AdamantaneIBA
04/2006
1Retinaldehyde (Retinal)IBA
04/2006

Therapy/Procedure

1Resuscitation
05/2006